Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)
NCT07547878 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 64
Last updated 2026-05-08
Summary
The goal of this clinical trial is to learn if starting four kidney disease medicines quickly and together (a rapid treatment approach) is safe and works well in people with type 2 diabetes and chronic kidney disease.
The main questions it aims to answer are:
* Is it safe to start these medicines over a short period of time?
* How often do kidney function changes or high potassium levels occur?
* Does this approach lower protein in the urine (a sign of kidney damage)?
* How many participants are able to stay on all four medicines over 6 months?
Researchers will compare this approach to usual care, where medicines are started one at a time over several months.
Participants will:
Be assigned by chance to either this approach or usual care Start up to four approved kidney medicines over about 8 weeks (rapid treatment approach) or follow standard care Have regular clinic visits and lab tests to check kidney function and potassium levels Be followed for about 6 months
Conditions
Interventions
- DRUG
-
10-40mg daily
- DRUG
-
.25-1.0mg 1 time a week
- DRUG
-
Lotensin
10-40mg daily
- DRUG
-
Capoten
12.5-50mg 3 times a day
- DRUG
-
Enalapril
2.5-10mg daily
- DRUG
-
Monopril
10-40mg daily
- DRUG
-
Lisinopril
5-20mg daily
- DRUG
-
Univasc
3.75-15mg daily
- DRUG
-
Aceon
4-16mg daily
- DRUG
-
Accupril
10-40mg daily
- DRUG
-
Altace
1.25-5mg daily
- DRUG
-
Mavik
1-4mg daily
- DRUG
-
Edarbi
40-80mg daily
- DRUG
-
Atacand
8-32mg daily
- DRUG
-
Avapro
150-300mg daily
- DRUG
-
Cozaar
25-100mg daily
- DRUG
-
Benicar
20-40mg daily
- DRUG
-
Micardis
20-80mg daily
- DRUG
-
Diovan
80-320mg daily
- DRUG
-
Invokana
100mg daily
- DRUG
-
10mg daily
- DRUG
-
Jardiance
10mg daily
- DRUG
-
Ertugliflozin
5mg daily
- DRUG
-
Brenzavvy
20mg daily
- DRUG
-
Sotagliflozin
200-400mg daily
Sponsors & Collaborators
-
Baylor Research Institute
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 84 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-04-30
- Primary Completion
- 2029-03-31
- Completion
- 2029-03-31
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Efficacy, Safety and Tolerability of Balcinrenone/Dapagliflozin Compared to Dapagliflozin in Adults With Chronic Kidney Disease
NCT06350123 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.
NCT06268873 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Pharmacodynamic Study of Measured Glomerular Filtration Rate in Patients With Chronic Kidney Disease and Type 2 Diabetes
NCT01500798 ·Status: TERMINATED ·Phase: PHASE1
-
Treatment of Patients With Diabetic Kidney Disease
NCT06187493 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
A Study of Atrasentan on Reducing Albuminuria in Type 2 Diabetic Nephropathy Treated With Renin-Angiotensin System Inhibitors
NCT00920764 ·Status: COMPLETED ·Phase: PHASE2
-
A Biomarker-targeted Clinical Trial to Optimize Treatment for Patients With Chronic Kidney Disease
NCT07239570 ·Status: RECRUITING ·Phase: PHASE4
-
A Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney Disease
NCT04492722 ·Status: TERMINATED ·Phase: PHASE2
-
Dapaglifozin to Avoid Acute Kindey Injury (AKI) to Chronic Kidney Disease (CKD) Transition: DAKI-CKD Study
NCT05713851 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Pharmacokinetics, Pharmacodynamics, and Safety Study of Ticagrelor in Hemodialysis Patients and Healthy Subjects
NCT02022748 ·Status: COMPLETED ·Phase: PHASE1
-
A Pharmacodynamic/Pharmacokinetic Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus on Treatment With Lisinopril
NCT01398267 ·Status: COMPLETED ·Phase: PHASE1
-
A Dose Escalation and Safety Study of I5NP to Prevent Acute Kidney Injury (AKI) in Patients at High Risk of AKI Undergoing Major Cardiovascular Surgery (QRK.004)
NCT00683553 ·Status: TERMINATED ·Phase: PHASE1
-
Effect of Renin-angiotensin System Blockers on Glomerular Filtration Rate in Patients With Hypertension, Type 2 Diabetes With Normoalbuminuria
NCT01500590 ·Status: UNKNOWN ·Phase: PHASE4
-
A Study to Evaluate the Effect of MK-5684 in Male Participants With Severe Renal Impairment (RI) and With End-stage Renal Disease (ESRD) (MK-5684-010)
NCT06814132 ·Status: COMPLETED ·Phase: PHASE1
-
Medicine-induced Cardiac Hemodialysis on COVID-19
NCT05711810 ·Status: COMPLETED ·Phase: PHASE4
-
The Efficacy and Safety of Sodium-glucose Cotransporter 2 Inhibitors in Patients With Acute Kidney Disease
NCT06528405 ·Status: RECRUITING ·Phase: PHASE2
-
Study on the Safety of the Drug Runcaciguat and How Well it Works When Given at the Highest Dose as Tolerated by Individual Patient Whose Kidneys Are Not Working Properly and Suffering at the Same Time From High Blood Sugar and/or High Blood Pressure and a Disease of the Heart and the Blood Vessels.
NCT04507061 ·Status: COMPLETED ·Phase: PHASE2
-
Effect of Repeated Doses of BI 1060469 and BI 1021958 on Glomerular Filtration Rate (GFR) in Healthy Volunteers
NCT02202512 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Efficacy of Oral GKT137831 in Patient With Type 2 Diabetes and Albuminuria
NCT02010242 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase I Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD5004
NCT06742762 ·Status: COMPLETED ·Phase: PHASE1
-
The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD
NCT05374291 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE3
-
Evaluate the Efficacy and Safety of Once Daily Administration of Atrasentan Tablets (Low and High) Compared to Placebo in Reducing Residual Albuminuria in Type 2 Diabetic Patients With Nephropathy Who Are Treated With the Maximum Tolerated Labeled Dose of a Renin Angiotensin System (RAS) Inhibitor
NCT01356849 ·Status: COMPLETED ·Phase: PHASE2
-
Dapagliflozin in Non-diabetic Stage IV CKD
NCT04794517 ·Status: COMPLETED ·Phase: PHASE2
-
Acute Kidney Injury in Patients on Dapagliflozin and Other Antidiabetic Medications
NCT02695082 ·Status: COMPLETED
-
Angiotensin-Neprilysin Inhibition in Hemodialysis Initiation
NCT05498181 ·Status: RECRUITING ·Phase: PHASE2
-
Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)
NCT06087835 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3